With breast cancer being the most common cancer diagnosis, and the leading killer unfortunately, new therapies are urgently needed. Unfortunately,-immunotherapy, there is little activity breast cancer. Breast cancer as traditionally not been considered and neurogenic tumor i.e. not a immunologically half. Importantly, triple negative breast cancer, has been noted to be slightly hotter than the other variants. Immune infiltration of the noted to be a good prognostic marker. The anti-PD—L1 monoclonal antibody, Atezolizumab, has shown significant activity. Further studies are required to further define its role.